Patent intelligence · US
US 12156863
Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound
Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound
Patent details — US 12156863
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 3, 2024
- Expiration
- Nov 28, 2044
- Applicant
- Galera Labs, LLC
- Claims
- 32
- CPC classes
- A61K, A61K31/198, A61K31/375, A61K31/555
Quick answer
US 12156863 (Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound) is held by Galera Labs, LLC. Status: granted. Granted Dec 3, 2024. Expires Nov 28, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Galera Labs, LLC
- Grant date
- Expiration
- Claims
- 32
- CPC classes
- A61K, A61K31/198, A61K31/375, A61K31/555, A61K31/635, A61K31/7135
More from Galera Labs, LLC
Related pharmaceutical patents in our USPTO index.
-
US 12220420
Combination therapy for cancer treatment
granted -
US 12077549
Pentaaza macrocyclic ring complexes possessing oral bioavailability
granted -
US 11826373
Methods for treatment of diseases
granted -
US 11612608
Methods of treating oral mucositis
granted -
US 11246950
Combination cancer immunotherapy with pentaaza macrocyclic ring complex
granted -
US 11219614
Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound
granted -
US 11066433
Pentaaza macrocyclic ring complexes possessing oral bioavailability
granted
Frequently asked questions
What is US patent 12156863?
US 12156863 (Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound) is held by Galera Labs, LLC. Status: granted. Granted Dec 3, 2024. Expires Nov 28, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12156863?
Galera Labs, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 23 pharmaceutical patents for this assignee.
When does US 12156863 expire?
Our index shows an expiration date of Nov 28, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.